Stay Informed. Stay Competitive with FREE Insights on the Stock Market, Dow 30 & Emerging Opportunities. Get Free Email Updates

Stay Competitive With Stock Market Updates!

Get Free Updates

“Markets Rise In Face of Middle East Tensions” Vista Partners Daily Market Recap For January 6, 2020

By John F. Heerdink, Jr.

We have just completed the first day of the first full week of trading of the new year and it was a bit of a roller coaster. The markets were met with an ugly hangover and sluggish weight from the rising tensions in the middle east as the widely reported footage of massive crowds in Tehran for the funeral of  Maj. Gen. Qassim Suleimani continued to spread. Initially, the markets seemed to be in a free fall sort of in reaction, but by the end of the day the fear and worry seemed to be shrugged off and the markets recovered to end the day in green territory across the board.

On the day, the S&P 500 ended at 3,246.28, +.35%. The S&P 500 communication services sector was the leader ending +1.2% as the FAANG stocks pushed forward closing as follows: Alphabet (GOOG) $1394.21/share, +2.47%, Facebook (FB) $212.60/share, +1.9%, Amazon (AMZN) $1902.88/share, +1.5%, Apple (AAPL) $299.80/share ,+.8%, & Netflix (NFLX), $335.83/share, +3.05%.

The Dow Jones Industrial Average ended at 28,703.38, +.24%. The Nasdaq Composite moved well above the 9k level and ended at 9,071.47, +.56% but shy of its recently achieved record high of 9,093.43.

The Russell 2000 also joined the green party moving higher by +.14% ending at 1663.26.

The “fear gauge” Vix (TVIX) also ended down at $50.77/share, -2.18% and traded in a range of $50.75 – $55.24.

Two cybersecurity-related firms rose in light of the recent hacking issues associated with the middle east tensions. CrowdStrike (CRWD) closed at $55.11/share,+8.6% and Finjan Holdings (FNJN) closed at $2.20/share, +9.45%.


Symbol Name Last Price Change % Change

Big Movers

Shares of Bilibili Inc. (BILI) jumped another 5.12% today closing at $23.21/share after achieving a new 52-wk high of $23.45. The 52-wk range is 13.23 – 23.45.

Bilibili is a leading online entertainment platform for young generations in China. They announced its unaudited financial results for the third quarter ended September 30, 2019 back on November 18, 2019. Total net revenues reached RMB1,859.0 million (US$260.1 million), a 72% increase from the same period in 2018. Average monthly active users (MAUs1) reached 127.9 million, mobile MAUs reached 114.2 million, representing increases of 38% and 43% from the same period in 2018, respectively. Average daily active users (DAUs) reached 37.6 million, a 40% increase from the same period in 2018.

Shares of San Francisco’s Salesforce (CRM) rose to a new all-time high of 173.63/share before closing at $173.45/share, +4.4%. RBC Capital Markets raised its rating to a “Top Pick” today as this monster CRM and acquisition machine continues to grow.


Symbol Name Last Price Change % Change

Bond Markets & US Dollar

Treasuries yields results were higher today. The 2-yr yield rose 3 basis points to close at 1.54% while the 10-yr yield rose two basis points to end at 1.81%. The U.S. Dollar Index weakened to end at 96.66, -.2%.


Symbol Name Last Price Change % Change

Economic Reports

We did not receive any significant economic data today.

Agriculture & Energy

Oil prices closed at $63.26/bbl, +.4%.

Symbol Name Last Price Change % Change

Biotech & Healthcare

The S&P 500 healthcare sector closed at 1187.27, +.59%.

The Ishares Nasdaq Biotechnology ETF (IBB) moved higher today closing at $119.12, +.64%.  The 52-wk range is $96.03 – $123.74.

The NYSE Arca Biotech Index (^BTK) closed at 5,034.52, +.99%.

Johnson & Johnson (JNJ) closed at $144.10, -.12%.


Shares of Atossa Therapeutics,  Inc. (NASDAQ: ATOS) closed at $1.58/share. Today, ATOS announced that its corporate name change from “Atossa Genetics Inc.” to “Atossa Therapeutics, Inc.” became effective at 12:01 a.m. ET today, January 6, 2020. The Company’s common stock will continue to trade on the NasdaqCM exchange under the ticker symbol “ATOS.”

“Over the last several years, we have transitioned the Company’s focus on developing therapies to treat breast cancer, breast density and other breast conditions,” said Steve Quay, Ph.D., M.D., president and CEO of Atossa. “Changing our name to Atossa Therapeutics, Inc. more clearly reflects our focus on developing therapies and continues to honor Princess Atossa, the great queen of the Achaemenid Empire, who reigned in the fifth century BCE and who is the earliest recorded woman with breast cancer. She is featured in the The Emperor of All Maladies: A Biography of Cancer, the Pulitzer Prize-winning book by Siddhartha Mukherjee on the history of cancer.”

Recently,  ATOS announced that it has contracted with Stockholm South General Hospital in Sweden to conduct a Phase 2 study of Atossa’s proprietary oral Endoxifen to reduce mammographic breast density (MBD) in women. The study is being led by principal investigator Per Hall, M.D., Ph.D., Head of the Department of Medical Epidemiology and Biostatistics at Karolinska Institutet. MBD is an emerging public health issue, as studies conducted by others have shown that MBD increases the risk of developing breast cancer and that reducing MBD can reduce the incidence of breast cancer. The primary endpoint of the new Phase 2 study is to determine whether oral Endoxifen administration results in an individual change in MBD, which will be measured after three and six months of treatment. The secondary endpoints are safety and tolerability. Assuming the institutional review board (IRB) approves the study, enrollment is expected to open in the first quarter of 2020.

Steve Quay, M.D., Ph.D., President and CEO of Atossa stated, “Atossa’s primary strategic objective is to develop oral Endoxifen to reduce MBD and this Phase 2 study is a major milestone in advancing this objective. Dr. Hall and his clinic are uniquely qualified to lead this study as they recently successfully completed the Phase 2 study of our topical Endoxifen, which demonstrated MBD reduction and they have conducted numerous studies using tamoxifen in both the treatment and prevention setting.”

Maxim Group’s Analyst Jason McCarthy recently issued an update report upgrading ATOS shares to a Buy with a $4/share 12-month price target, stating that the company is “ready to advance its modified-release oral tablet of endoxifen to a P2 study for the treatment of mammographic breast density (MBD).”

INVO Bioscience, Inc. (IVOB) is a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell®, the world’s only in vivo Intravaginal Culture System, & recently announced that it has entered into commercialization agreements to distribute the revolutionary INVOcell system across many parts of the world including the continent of Africa, covering Nigeria, Uganda, Sudan, and Ethiopia, as well as in Europe (Turkey & Jordan) & the US. Steve Shum (pictured above), Chief Executive Officer of INVO Bioscience, commented recently, “We are excited with the progress being made to drive revenue growth domestically through our U.S. commercialization agreement with Ferring and now in other parts of the world with the recent signing of new commercial distribution agreements for Nigeria, Turkey, Jordan, Uganda, Ethiopia, and Sudan. We believe there is an incredible opportunity to drive the adoption of the INVOcell over the coming years through the creation of commercialization agreements with partners. We will remain diligent to find partners that are incentivized to support the product through minimum purchase requirements or similar arrangements. Our agreement with Ferring for the U.S. and our recent agreements for Africa and Eurasia are great templates to continue working from and we look forward to further agreements announced in the future. Other near-term objectives include the initiation of our follow-on clinical study for the INVOcell device to expand S current label from a 3-day incubation period to a 5-day incubation period. As part of the Ferring agreement, if we achieve 5-day labeling approval from the FDA, we receive an additional $3 million non-dilutive milestone payment. In addition to the milestone payment, the new study will allow us to update our clinical data which we believe will allow us to show improved clinical pregnancy and birth rates and further enhance the value proposition we can provide to the market as an alternative to traditional IVF. Our technology is a simple and more natural solution, with comparable rates of effectiveness to existing options at lower costs, that has been designed to help the millions of couples worldwide that struggle with infertility but are currently unable to receive treatment. We are beginning to put in place the commercialization strategy that can allow for the proliferation of this technology which I believe has the ability to significantly enhance shareholder value.”

Symbol Name Last Price Change % Change

Consumer Goods & Trends

Shares of Nike (NKE) closed at $101/83/share, -.09% today.

Shares of Disney (DIS) closed at $145.65/share, -.58%. Recently, Rosenblatt Securities stated that they expect 20% more Disney+ streaming service subscribers than was expected by the end of Q1 2020 which would mean they could have 25 million subscribers.

Symbol Name Last Price Change % Change

Financials & Fintech

Visa (V) closed trading at $191.12/share, +1.71%. Recently, Visa and the pan-African fintech leader MFS Africa announced a partnership that will help bridge the gap between the rapidly growing mobile money ecosystem in Africa and the world of online digital payments, significantly expanding Visa’s reach and its ability to open up commerce to the region.

Symbol Name Last Price Change % Change

Materials & Natural Resources


Gold prices closed at $1,561.30/0z, -.48%.

Silver closed lower at $18.07/oz, -.60%.

First Majestic Silver (AG) closed at $11.65/share, -2.67%. AG recently hit a new 52-wk high of $12.26/share after reporting their Q3 2019 earnings where CEO Keith Neumeyer highlighted that they added $21.4 M to their treasury during the quarter as a result of strong production from San Dimas and Santa Elana mines.

Hecla Mining Company (HL) closed at $3.31/share, -1.19% after reaching a new 52-wk high of $3.51 recently. On Tuesday, Dec. 16th, HL reported that the union workers have voted not to ratify the Tentative Agreement reached by the USW and Hecla negotiating committees. The Company is committed to bringing the mine back to full production and is increasing the hiring of employees and contractors. “For much of 2019 we have employed a number of hourly workers who, combined with our salaried workforce, have operated the Lucky Friday on a limited basis,” said Phillips S. Baker, Jr., President and CEO. “We will now accelerate hiring and utilizing contractors with the goal of reaching full production by year-end 2020. While we would have preferred ratification of the agreement reached by the two negotiating committees, after three years of negotiating we believe the best interests of the company and community is the Lucky Friday in full operation. The mine has operated for 75 years, and we believe its best days with projected higher grades and more cash flow, are in front of it. I want to acknowledge the existing salaried and hourly staff at the Lucky Friday, who kept the mine operating during the strike and in doing so have helped minimize the financial impact. But most importantly, they have operated in a very safe manner, and were recognized for their efforts by receiving the highest mine safety award in the United States, the Sentinels of Safety from the National Mining Association, earlier this fall.”

Symbol Name Last Price Change % Change

Technology & Beyond

The FAANG stocks closed as follows:

  • Facebook (FB) $212.60/share, +1.9%
  • Amazon (AMZN) closed at $1902.88/share, +1.5%
  • Apple (AAPL) closed at $299.80/share ,+.8%
  • Netflix (NFLX) $335.83/share, +3.05%
  • Alphabet (GOOG) $1394.21/share, +2.47%



Symbol Name Last Price Change % Change

Investing & Inspiration

“I rarely think the market is right. I believe non-dividend stocks aren’t much more than baseball cards. They are worth what you can convince someone to pay for it.” -Mark Cuban

Michael Marcus taught me one other thing that is absolutely critical: You have to be willing to make mistakes regularly; there is nothing wrong with it. Michael taught me about making your best judgment, being wrong, making your next best judgment, being wrong, making your third best judgment, and then doubling your money.” -Bruce Kovner

“The policy of being too cautious is the greatest risk of all.” -Jawaharlal Nehru

“The only true test of whether a stock is “cheap” or “high” is not its current price in relation to some former price, no matter how accustomed we may have become to that former price, but whether the company’s fundamentals are significantly more or less favorable than the current financial-community appraisal of that stock.” -Philip Fisher

“I learned to avoid trying to catch up or double up to recoup losses. I also learned that a certain amount of loss will affect your judgment, so you have to put some time between that loss and the next trade.” -Richard Dennis

Symbol Name Last Price Change % Change


We are due to receive the ISM Non-Manufacturing Index report for December, the Trade Balance Report for November and the Factory Orders Report for November on Tuesday.




Here are three trading ideas in biotech to check out:

  • Acorda Therapeutics (ACOR) which closed at $1.96/share last Thursday when we originally highlighted them after they recently announced a $276M exchange of convertible senior debt that moved maturity out to 2024, closed today’s trading up another +9.25% closing at $2.48/share.


  •  Aduro Biotech, Inc. (ADRO) closed at $1.18/share last Thursday and has interesting data points due in the 1st half 2020. Today it closed up another +9.92% closing at $1.33/share.


  • Neubase Therapeutics (NBSE) closed trading at $6.90/share last Thursday and expects several data points to be released in the 1st half of 2020 with regard to their gene silencing platform that is initially targeting HD and ALS. Today NBSE closed up again at $7.19/share, +1.70%.



Please consider viewing these interesting videos: